Amedes Group
Amedes Group is a physician-founded German medical diagnostics provider operating 100+ lab and practice locations in Germany and Belgium. It serves 600,000+ patients annually with 4,400 staff, offering interdisciplinary lab medicine, genetics, cytology, pathology, and prenatal testing billed through statutory and private insurance.
- Company typePrivate
- Founded1987
- HeadquartersHamburg, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Amedes Group does
Amedes Group is a privately held German medical diagnostics company founded in 1987, operating as amedes Medizinische Dienstleistungen GmbH (with amedes Holding GmbH as the parent holding). The group runs an interdisciplinary network of more than 100 laboratory and practice locations across Germany and Belgium, staffed by approximately 4,400 employees and processing more than 580,000 laboratory analyses per day for over 600,000 patients annually. Its service portfolio spans twelve medical disciplines, including laboratory medicine, cytology, pathology, human genetics, microbiology, reproductive medicine, rheumatology, endocrinology, gynecology, prenatal medicine, gastroenterology, and hemostaseology, with a stated positioning as a physician-founded, physician-serving ("Von Ärzten – für Ärzte") provider.
The group operates a B2B2C model: it serves individual patients (e.g., through the amelis online portal and mobile app for retrieving results), refers from outpatient physicians (niedergelassene Ärzte) and clinics/hospitals. Core digital products include the amelis patient portal, the amedes fetalis non-invasive prenatal test (NIPT) for fetal Rhesus D determination (covered by statutory insurance since July 2021), the Baby Health Check extended newborn screening program, and the Amelie chatbot for physician order entry. Consumer-facing sub-brands include BiomCheck, VaginomCheck, genactive slim, and the Liquid Biopsy Center. The company publishes amedes UPDATE (triannual customer magazine) and AMEDES ABRECHNUNGSNEWS (quarterly reimbursement newsletter) and runs continuing medical education events.
Revenue is generated transactionally on a per-test basis, billed to statutory health insurers (GKV) via the EBM fee schedule and to private insurers (PKV) via the GOÄ schedule, with additional self-pay/IGeL revenue and physician billing services. M&A history includes the February 2023 acquisition of Austrian rare-disease diagnostics specialist ARCHIMEDlife. Leadership transitioned in April 2025 with Dr. Marc-Alexander Burmeister replacing Wolf Kupatt as CEO. The company is investing in infrastructure, including the NewHome Göttingen campus (opened October 2025) and a Hamburg laboratory consolidation scheduled for 2026.
Amedes Group firmographics
Firmographics- Name
- Amedes Group
- Legal name
- amedes Medizinische Dienstleistungen GmbH
- Website
- https://amedes-group.com
- Company type
- Private
- Founded year
- 1987
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Amedes Group is a physician-founded German medical diagnostics provider operating 100+ lab and practice locations in Germany and Belgium. It serves 600,000+ patients annually with 4,400 staff, offering interdisciplinary lab medicine, genetics, cytology, pathology, and prenatal testing billed through statutory and private insurance.
- Ownership category
- akta.pro rank
Amedes Group industry classification
Industry- Product category
- Medical Diagnostic Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Reference & Esoteric Testing Laboratories (HLAFAMAJ)
- akta.pro secondary industries
- Genetic & Prenatal Testing Laboratories (HLAFAMAH), Independent Diagnostic Testing Facilities (IDTFs) & Multi-Specialty Diagnostic Centers (HLAFAKAN)
Keywords
Where Amedes Group is headquartered
LocationHeadquarters
- HQ city
- Hamburg
- HQ country
- Germany
- HQ region
- Europe
Offices9 records
Markets served
Amedes Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Laboratory Diagnostic Services: Amedes generates revenue primarily through medical laboratory diagnostic services billed to statutory health insurance (GKV/Gesetzliche Krankenversicherung) via the EBM (Einheitlicher Bewertungsmaßstab) billing system and to private health insurance (PKV) via GOÄ (Gebührenordnung für Ärzte). Revenue is transaction-based per laboratory test performed. The company also generates revenue from billing services for physicians (Abrechnungsservice) and from self-pay/IGeL services not covered by insurance.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels11 records
Amedes Group product offering
Product offeringCore offering
Amedes Group provides interdisciplinary medical diagnostic services across more than 100 laboratory and practice locations in Germany and Belgium, covering laboratory medicine, human genetics, cytology, pathology, microbiology, and reproductive medicine. The group delivers results to patients and physicians through a digital portal (amelis) and offers specialized testing products such as non-invasive prenatal screening (fetalis), extended newborn screening (Baby Health Check), and liquid biopsy cancer diagnostics. Revenue is generated primarily per laboratory test performed, billed under the German EBM (statutory) and GOÄ (private) fee schedules.
Product overview
Amedes Group operates as an interdisciplinary medical diagnostic services provider offering a portfolio of products and services across over 100 laboratory and practice locations in Germany and Belgium. The core offering includes laboratory medicine, cytology, pathology, and human genetics services. Key digital products include amelis (online results portal), amedes fetalis (non-invasive prenatal testing), and Baby Health Check (extended newborn screening). The group also operates specialized centers including the Liquid Biopsy Center for cancer diagnostics, and offers consumer-facing brands like BiomCheck, VaginomCheck, and genactive slim. Publications include amedes UPDATE (triannual customer magazine) and AMEDES ABRECHNUNGSNEWS (quarterly reimbursement newsletter). Daily capacity exceeds 580,000 laboratory analyses serving over 600,000 patients annually.
Differentiator
Problem solved
Functional benefit
Brands
- amedes genetics: Genetics division providing genetic testing and analysis services
- fetalis
- amelis
- DIAMEDIS
- BiomCheck
- VaginomCheck
- genactive slim
- Liquid Biopsy Center
Products and services
- amelis Online platform that enables patients to view and retrieve medical diagnostic test results digitally via web portal or mobile app (Android/iOS), with secure login and encrypted data transfer.
- amedes fetalis (RhD-NIPT) Non-invasive prenatal test (NIPT) for fetal Rhesus D blood type determination, offered as a reliable and cost-effective screening solution for pregnant women.
- Baby Health Check Extended newborn screening program offered in addition to state-mandated screening, testing for an additional 14 or 70 rare diseases as an individual health service (IGeL).
- BiomCheck Biomarker testing service offered by amedes Group to patients.
- VaginomCheck Vaginal health screening and diagnostic service offered by amedes Group.
- Liquid Biopsy Center Advanced cancer diagnostics service using liquid biopsy technology for non-invasive tumor analysis, operated by amedes Group.
- genactive slim Genetic-based weight management health and wellness service offered by amedes Group.
- Labormedizin (Laboratory Medicine) Core laboratory medicine services including analytical testing and clinical diagnostics performed across 100+ laboratory and practice locations in Germany and Belgium.
- Humangenetik (Human Genetics) Human genetics services including genetic testing, genetic counseling, and prenatal diagnostics offered to physicians and patients.
- Pathologie (Pathology) Pathology services including histological examination and tissue diagnostics for hospitals, clinics, and referring physicians.
- Zytologie (Cytology) Cytology services including cervical cancer screening (Pap tests), dysplasia screening, and cell diagnostics.
- Mikrobiologie (Microbiology) Microbiology diagnostic services including infectious disease testing offered to physicians and hospitals.
- Reproduktionsmedizin (Reproductive Medicine) Reproductive medicine services including fertility diagnostics and assisted reproduction support offered to patients and referring physicians.
Quantifiable outcome
- Over 580,000 laboratory analyses processed daily across the network
- +1 more outcomes
Companies that use Amedes Group
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Amedes Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
Feature4 records
Amedes Group partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ARCHIMEDlife International Medical LaboratorycoreAmedes acquired ARCHIMEDlife to 100% in February 2023, making it a wholly-owned subsidiary. ARCHIMEDlife is an Austrian diagnostic service provider specializing in rare disease diagnostics and newborn screening. The acquisition expanded amedes' capabilities in newborn screening (Baby Health Check program) and rare disease testing.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Amedes Group competitors and assessment
Company assessmentDirect peers
- Synlab AG: Synlab is Europe's largest medical diagnostics services provider, operating a similar network of clinical laboratories and offering an overlapping test menu (clinical chemistry, genetics, cytology, pathology). It is amedes' closest direct competitor in the German and broader European laboratory market.
- Unilabs: Unilabs is a pan-European clinical laboratory and diagnostic services provider headquartered in Switzerland. It competes with amedes in routine and specialty diagnostics across multiple European countries, sharing the same B2B model serving physicians and hospitals.
- LADR Der Laborverbund Dr. Kramer & Kollegen: LADR is a German laboratory network providing medical diagnostic services to physicians and hospitals across northern Germany. It is a direct peer in the same physician-referral lab services model with overlapping test menu and reimbursement structure.
- Limbach Gruppe SE: Limbach Gruppe is a German medical diagnostics group operating laboratory and pathology services across multiple German regions. It competes directly with amedes in clinical laboratory diagnostics and specialty testing for office-based physicians.
Broad incumbents
- Sonic Healthcare: Sonic Healthcare is a global medical diagnostics company with substantial European operations (including Germany via acquired lab groups). It is a much larger incumbent offering a comparable portfolio of clinical laboratory, pathology, and radiology services.
- Helios Kliniken (Fresenius): Helios, part of Fresenius, operates Germany's largest private hospital chain and performs significant in-house diagnostic testing. It is a broad incumbent whose diagnostic volumes partly compete with amedes' clinic channel and influence in-hospital lab outsourcing decisions.
- Eurofins Scientific: Eurofins is a global laboratory testing services group with significant clinical diagnostics exposure in Europe. It competes with amedes in clinical and esoteric testing, though its portfolio is much broader including food, environmental, and pharma testing.
Regional players
- MVZ Labor Dr. Limbach & Kollegen: A regional German medical laboratory network providing diagnostic services to physicians and clinics. It overlaps with amedes' core offering in routine and specialty laboratory diagnostics within overlapping German geographies.
- Labor Berlin: Labor Berlin is one of Europe's largest hospital laboratories, a joint venture between Charité and Vivantes. It competes for hospital-based diagnostic contracts in Germany and represents a regional alternative for clinic laboratory services.
Emerging players
- Centogene AG: Centogene is a Germany-based rare disease and genetic diagnostics company. It overlaps with amedes' genetics, newborn screening, and rare disease testing lines (particularly via the ARCHIMEDlife acquisition) and competes for specialized genetic testing referrals.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Amedes Group social profiles
Digital presenceAmedes Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Amedes Group leadership team
Management profileNumber of profiles
Profiles3 records
Amedes Group subsidiaries and ownership
Company hierarchySubsidiaries1 record
Amedes Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Amedes Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Amedes Group
What does Amedes Group do?
Amedes Group provides interdisciplinary medical diagnostic services across more than 100 laboratory and practice locations in Germany and Belgium, covering laboratory medicine, human genetics, cytology, pathology, microbiology, and reproductive medicine. The group delivers results to patients and physicians through a digital portal (amelis) and offers specialized testing products such as non-invasive prenatal screening (fetalis), extended newborn screening (Baby Health Check), and liquid biopsy cancer diagnostics. Revenue is generated primarily per laboratory test performed, billed under the German EBM (statutory) and GOÄ (private) fee schedules.
Is Amedes Group a public or private company?
Amedes Group is a private company. It is classified as management employee owned and is currently operating.
When was Amedes Group founded?
Amedes Group was founded in 1987. It employs 11 to 50 people.
Where is Amedes Group based?
Amedes Group is headquartered in Hamburg, Germany, in the Europe region.
How does Amedes Group make money?
One revenue line is on record: laboratory Diagnostic Services.
Who are Amedes Group's main competitors?
Direct peers on record are Synlab AG, Unilabs, LADR Der Laborverbund Dr. Kramer & Kollegen and Limbach Gruppe SE. Broad incumbents are Sonic Healthcare, Helios Kliniken (Fresenius) and Eurofins Scientific. Regional players are MVZ Labor Dr. Limbach & Kollegen and Labor Berlin. Centogene AG is listed as an emerging player.
Does Amedes Group have an API?
No public API is recorded for Amedes Group.
What industry is Amedes Group in?
Amedes Group's product category is Medical Diagnostic Services. Its primary akta.pro industry code is HLAFAMAJ, Reference & Esoteric Testing Laboratories, with a secondary code of HLAFAMAH, Genetic & Prenatal Testing Laboratories. Its NAICS code is 621511 and its SIC code is 8071.